Hereditary neuropathy with liability to pressure palsies (HNPP) is a dominantly inherited disorder that presents as recurrent mononeuropathies precipitated by apparently trivial traumas. The presence of a deletion in 17pll-2 was analysed in 13 Finnish families with HNPP. The deletion was found in all patients who were neurologically and neurophysiologically confirmed to have HNPP. In the problematic cases the detection of the gene defect is the method of choice in the diagnosis of HNPP. Analysis of DNA can also be used to detect clinically unaffected family members.
Hereditary neuropathy with liability to pressure palsies (HNPP) (MIM number 162 500) is a dominantly inherited disorder that presents as recurrent mononeuropathies precipitated by apparently trivial traumas. ' Typically, the onset of symptoms occurs in the second or third decade. Neurological examination shows weakness and sensory loss in the distribution of the affected nerve and many patients also have signs of a more generalised neuropathy. The Gene copy number was estimated by visual assessment of polymorphic bands on autoradiograms and corroborated by measurement of band density and comparison with control marker (SF85) using a densitometric analysis (MCID, Image Analysis System).
Nerve biopsies were processed for semithin epon section, teasing, and electron microscopy according to our modification of the previously published method.10
Results
All 33 patients from 13 families (fig 1) who /Lbbb were clinically and neurophysiologically (two of them also neuropathologically) confirmed t)
to have HNPP harboured the deletion in b b/b 17pll -2. The deletion was also detected in the five patients who were clinically affected but not neurophysiologically examined. In all affected patients the presence of the deletion was determined by comparing the relative intensity of the I17pll 2 band with the constant band of the reference probe SF85 on EcoRI digestion (fig 2) . The intensity differences noticed by visual inspection were confirmed by densitometric analysis. Due to the 1-differences in labelling and hybridisation in each film, the calculated ratio of the signals for pVAW409R3a and SF85 differed significantly between affected and non-affected patients. Thus only the ratios within the same film could be compared. The ratios for the patients were about half of the ratios for the X control patients in each film (table) . b
In all families the segregation of pVAW409R3a/MspI alleles was also fol--lowed. Nine families were informative and a a loss of a pVAW409R3a allele was found. For -ted with example, in family 8 ( fig 2) the two affected ith . males (II-1 and II-2) are hemizygous for the led by pVAW409R3a locus. They have inherited their only 1 9 kb allele (c) from their healthy mother and no pVAW409R3a allele from their affected father. Similarly III-2 has inherited the 2-8 kb allele (a) from her healthy Z2) and mother and no allele from the affected father. ), both The deletion was also detected in four subjeckhoven tively healthy subjects (III-1 in family 4, II-2 verpen, in family 7, II-2 in family 10, and I-2 in famcts on ily 12) who had no history of mononeurb, and ropathies but who have not been clinically or onstant neurophysiologically examined. SF85 The transmission of the deletion (also male it band to male) through three generations was seen on one in two families and in eight families deletion was found in two generations confirming the autosomal dominant inheritance of HNPP. In these patients the value of the DNA analysis is obvious. In our data a loss of a pVAW409R3a allele was easily seen on analysing several members of nine informative families out of 13 studied. In these cases the diagnosis of HNPP is conclusive. When DNA analysis is used diagnostically in a single case, however, it is recommended that two 17pll 2 probes are used as in the diagnostic test for CMTla,'2 because the control and patient ranges for one probe may overlap (table) .
Although HNPP is a benign disorder, we believe that the gene defect should be identified in clinically unaffected family members at an early age. If the patients are aware of their liability to develop pressure neuropathies they may avoid situations where their nerves may become exposed to chronic pressure either at work or at leisure time.
So far there have been no specific laboratory tests for HNPP. Diagnosis of HNPP has relied on medical history, clinical, neurophysiological, and neuropathological findings, and on heredity. In most of our patients the tentative diagnosis of HNPP was made when a patient with mononeuropathy showed generalised abnormalities of nerve conduction. If the patient had the typical clinical presentation and neurophysiological findings the diagnosis of probable HNPP was made. Subsequently the family members were studied. If another family member showed the typical neurophysiological findings the diagnosis was definite HNPP. Nerve biopsy was done on only two patients. We believe that nerve biopsy, which may cause considerable inconvenience to the patient, is not to be recommended in this benign disorder, all the more now with the DNA diagnostics available. The accuracy of diagnosis based on medical history, heredity, and neurophysiological findings is shown by our study: all the patients diagnosed as having HNPP harboured the 17p 112 deletion.
